Sanjeev Nanda to Aid in the Development of Russian Pharmaceutical Infrastructure through ISHVAN Pharmaceuticals
Sanjeev Nanda, the British-Indian business baron is venturing into the pharmaceutical business with ISHVAN Pharmaceuticals Limited. The company which aspires to be a fully integrated pharmaceutical company will have its focus on manufacturing, development and supply of a variety of innovative and affordable medicinal drugs, medical devices and diagnostics to different pharmaceutical markets all over the world.
Sanjeev Nanda, an entrepreneur with vast experience and expertise was instrumental in establishing the Taj Hotel at Dubai. On top of that, he also setup “Billionaire Mansion” at the Taj Hotel Dubai, which serves as a unique dining venue offering original Italian cuisine to its guests and partnered with award winning Japanese restaurant, SUMOSAN. Sanjeev Nanda has a wealth of experience in running large organizations spread across different sectors such as heavy engineering, F&B, hotel & hospitality, IT and others.
He was also the mastermind behind the creation of the famous “Dhaba” which served as a unique charm of “The Claridges” hotel, also co-owned by Sanjeev Nanda. However on Dec’ 2016, the Dhaba by Claridges was sold to Azure Hospitality where Goldman Sachs and Max Ventures & Industries Limited are the investors.
The primary focus of the pharmaceutical company will be to offer turn-key solutions and expertise as well as bring in assistance towards improving the local Russian pharmaceutical infrastructure. Also, ISHVAN pharmaceuticals under the leadership of Sanjeev Nanda will put in every effort to offer patients with access to latest generation of medical drugs for treatment of diseases like TB, HIV and Hepatitis. In order to fulfill its objective, ISHVAN will target different markets in phases where first, it will focus on Russian and Eurasian markets then shift its focus towards Asian and African markets.
A way forward strategy has already been identified by ISHVAN pharmaceuticals and associations are being made with different foreign and Indian companies to evolve the business. After a lot of scrutiny, advanced negotiations are being made with reputed pharmaceutical companies like Laurus, Mylan, Cipla, etc. to acquire technology required for development and production of finished drugs (FDF) and drug substances (API). The company has also obtained MA’s (market authorization) from Cannon and Rowtec which is essential for the introduction of generic equivalent of a said product after expiry of the patent.
The vast number of available opportunities in the Russian market will be the fundamental driving force of ISHVAN pharmaceuticals. By bringing in the newer generation products from different partners, ISHVAN will present the Russian market with safer and effective medication as well as better treatment goals. Also the products are expected to take up a majority share in the market as there is no foreseeable or present competition. The operations of ISHVAN will start with a total investment of US $60 million in Russia by focusing on niche segments like HIV/AIDS, Hepatitis and TB. The HIV/AIDS population in Russia is the fastest growing in the world and Russia also happens to be the 8th most populated country in the world terms of HIV patients. Reports state that 70% of new incidences of HIV/AIDS affect the working population within the age bracket of 29-30 years.
Thus, the arrival of ISHVAN with its advanced solutions and new generation products is expected to help Russia put a stop to this growing concern. After establishing its operation in Russia, Sanjeev Nanda’s pharmaceutical firm will target the Eurasian market by bringing in IP backed novel drugs, newer treatment options and better platforms for therapy areas related to vaccines, oncology, blood products and biological drugs along with innovative options in devices and diagnostics. If all goes well, ISHVAN with its focus on driving innovation and technology in the field of pharmacy will certainly bring in huge improvements in global health issues throughout different geographies.
